熱門資訊> 正文

Zymeworks宣布关键管理变革

2026-01-12 20:32

Zymeworks Inc.(ZYME) 0

Clinical-stage biotechnology company Zymeworks (ZYME) said that Dr. Sabeen Mekan has been promoted to senior VP and chief medical officer, effective February 1, 2026.
Dr. Jeff Smith, current CMO, will be retiring effective January 31, 2026, while continuing to provide services as an adviser for a transitional time period.
Besides, Mr. Mark Hollywood has been promoted to executive VP and COO with expanded responsibilities.

More on Zymeworks

HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA
Zymeworks reports positive phase 3 Ziihera data; cash runway extended beyond 2028
Zymeworks shifts to a royalty-driven business model

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。